Actively Recruiting
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Led by Ontario Clinical Oncology Group (OCOG) · Updated on 2026-04-27
40
Participants Needed
5
Research Sites
192 weeks
Total Duration
On this page
Sponsors
O
Ontario Clinical Oncology Group (OCOG)
Lead Sponsor
P
Pfizer
Collaborating Sponsor
AI-Summary
What this Trial Is About
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
CONDITIONS
Official Title
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with relapsed and/or refractory multiple myeloma defined by disease progression during or within 60 days of last treatment
- Measurable disease according to IMWG criteria within 28 days before enrollment
- Received at least three prior classes of drugs including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 drugs
- Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less
You will not qualify if you...
- Active plasma cell leukemia with ≥20% of peripheral white blood cells or >2.0 × 109/L circulating plasma cells
- Amyloidosis
- POEMS syndrome
- Monoclonal gammopathy of unknown significance or smoldering multiple myeloma
- Solitary plasmacytoma
- Stem cell transplant within 12 weeks prior to enrollment or active graft versus host disease
- Prior treatment with a BCMA targeting agent
- Laboratory abnormalities within 28 days before enrollment including low neutrophils, low platelets, low hemoglobin, elevated liver enzymes, reduced kidney function, or high bilirubin
- Unable to stay within 60 minutes of travel to the study hospital for the first 9 days after first dose or without a caregiver to monitor temperature and support
- Significant heart conditions within 6 months prior to enrollment such as heart attack, serious arrhythmias, thromboembolic events, or prolonged QT syndrome
- Ongoing Grade 2 or higher peripheral neuropathy or history of Guillain-Barre Syndrome or severe motor polyneuropathy
- Unresolved effects of prior multiple myeloma therapy in the last 3 months worse than Grade 1
- Active infections including hepatitis B or C, HIV, SARS-CoV2, or uncontrolled infections
- Other active cancers within 2 years except certain skin cancers
- Serious unstable medical or psychiatric conditions or recent major surgery
- Known allergy to elranatamab or its components
- Recent cancer treatments or enrollment in another interventional study
- Recent live vaccinations or planned live vaccinations during the study
- Pregnancy, lactation, or inability to meet contraception requirements
- Inability to provide signed informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Vancouver Cancer Center
Vancouver, British Columbia, Canada, V5Z 1L3
Actively Recruiting
2
Juravinski Cancer Center
Hamilton, Ontario, Canada, L8V 1C3
Actively Recruiting
3
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
Actively Recruiting
4
London Health Science Centre - Victoria Hospital
London, Ontario, Canada, N6A 5W9
Not Yet Recruiting
5
Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
Research Team
E
Emilio Aguirre, CRA,HIT,CHIM
CONTACT
D
Daryl Solomon
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here